<DOC>
	<DOCNO>NCT02612662</DOCNO>
	<brief_summary>This first-in-human ( FIH ) study design evaluate safety , tolerability , pharmacokinetics ( PK ) AZD4076 tetracosasodium healthy male subject increase single dos .</brief_summary>
	<brief_title>A Study Assess Safety Tolerability Single Doses AZD4076 Healthy Male Subjects</brief_title>
	<detailed_description>This Phase 1 , randomize , first-in-human ( FIH ) study assess safety , tolerability , pharmacokinetics ( PK ) AZD4076 tetracosasodium follow subcutaneous ( SC ) administration healthy male subject increase single dos</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Provision sign date , write informed consent prior study specific procedures 2 . Healthy male subject age 18 50 year suitable vein cannulation repeat venipuncture 3 . Have body mass index ( BMI ) 18 30 kg/m2 inclusive weigh least 50 kg 100 kg inclusive 4 . Provision sign , write date informed consent optional genetic research 1 . History presence clinically significant disease disorder , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study 2 . History presence hepatic renal disease , condition know interfere distribution , metabolism , excretion drug 3 . History presence significant neurological psychiatric disease/mental illness ( judged investigator ) 4 . Suspicion know Gilbert 's syndrome base liver function test 5 . Any clinically significant illness , medical/surgical procedure , trauma within 4 week administration IMP 6 . Any clinically significant abnormality clinical chemistry , hematology , urinalysis result , judge investigator 7 . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) 8 . Serum Creatinine great ULN . 9 . Platelet count outside normal range . 10 . AST , ALT , GGT great ULN . 11 . Abnormal vital sign , 10 minute supine rest , define follow : Systolic BP ( SBP ) &lt; 90mmHg ≥ 140 mmHg Diastolic BP ( DBP ) &lt; 50mmHg ≥ 90 mmHg Pulse &lt; 45 &gt; 85 beat per minute ( bpm ) 12 . Any clinically significant abnormality rhythm , conduction morphology rest ECG clinically significant abnormality 12lead ECG , consider investigator may interfere interpretation QTc interval change , include abnormal STTwave morphology , particularly protocol define primary lead leave ventricular hypertrophy 13 . Prolonged QTcF &gt; 450 m shorten QTcF &lt; 340 m family history long QT syndrome 14 . PR ( PQ ) interval shorten &lt; 120 m ( PR &gt; 110 m &lt; 120 m acceptable evidence ventricular preexcitation ) 15 . PR ( PQ ) interval prolongation ( &gt; 240 m ) intermittent second ( Wenckebach block asleep exclusive ) third degree AV block , AV dissociation 16 . Persistent intermittent complete bundle branch block ( BBB ) , incomplete bundle branch block ( IBBB ) , intraventricular conduction delay ( IVCD ) QRS &gt; 110 m . Subjects QRS &gt; 110 m &lt; 115 m acceptable evidence , example , ventricular hypertrophy preexcitation 17 . Known suspected history drug abuse , judge investigator 18 . Current smoker smoke used nicotine product within 3 month prior screen 19 . History alcohol abuse excessive intake alcohol , judge investigator 20 . Positive screen drug abuse cotinine ( nicotine ) screen admission unit positive screen alcohol admission unit prior administration IMP 21 . History severe allergy/hypersensitivity ongoing clinically significant allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class AZD4076 tetracosasodium 22 . Excessive intake caffeine contain drink food ( e.g. , coffee , tea ) , judge investigator 23 . Use drug enzyme induce property St John 's Wort within 3 week prior administration IMP 24 . Use prescribed nonprescribed medication include antacid , analgesic ( paracetamol/acetaminophen ) , herbal remedy , megadose vitamin ( intake 20 600 time recommended daily dose ) mineral two week prior administration IMP long medication long halflife 25 . Plasma donation within one month screen blood donation/blood loss &gt; 500 mL 3 month prior screen 26 . Has receive another new chemical entity ( define compound approve marketing ) within 3 month administration IMP study . The period exclusion begin three month final dose one month last visit whichever long . Note : Subjects consent screen , randomize study previous phase I study , exclude . 27 . Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order 28 . Involvement Astra Zeneca , PAREXEL study site employee close relatives 29 . Judgment investigator subject participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction requirement 30 . Subjects vegans medical dietary restriction 31 . Subjects communicate reliably investigator In addition , follow regarded criterion exclusion genetic research : 32 . Previous bone marrow transplant 33 . Nonleukocyte deplete whole blood transfusion within 120 day date genetic sample collection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>AZD4076</keyword>
	<keyword>Healthy male subject</keyword>
	<keyword>Safety</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>Tolerability</keyword>
</DOC>